GleamWall
中文EN

OKUR OnKure Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1637715 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY2.5%
TTM EPS YoY-102.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-55.2%
ROA-51.6%
ROIC (approx.)-4,360.7%
Asset turnover—

Leverage & solvency

Liabilities / assets5.6%
Debt / equity0.00x
Current ratio18.84x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-11.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q42025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q42024-12-31
Income statement
Revenue————————
R&D expense$15.06M$12.61M$11.71M$10.72M$11.91M$12.61M$13.01M$37.36M
SG&A expense$4.29M$4.29M$3.91M$3.40M$3.59M$3.71M$3.99M-$3.56M
Operating income-$19.35M-$16.90M-$15.62M-$14.12M-$15.50M-$16.32M-$17.00M-$33.80M
Net income-$17.85M-$15.35M-$15.16M-$13.50M-$14.70M-$15.39M-$15.93M-$17.44M
EBITDA-$19.30M-$16.81M-$15.51M-$14.02M-$15.39M-$16.21M-$16.88M-$33.38M
EPS (basic)-0.36-0.31-1.11—-1.09-1.14-1.19—
EPS (diluted)-0.36-0.31-1.11—-1.09-1.14-1.19—
Weighted avg. shares (diluted)49.93M49.87M13.67M—13.53M13.51M13.42M—
Banking
Net interest income$1.50M$1.55M$458,000$622,000$802,000$934,000$1.07M$1.26M
Balance sheet
Cash & equivalents$151.44M$166.50M$192.11M$59.05M$70.33M$83.37M$96.66M$110.76M
Short-term investments$11.86M$9.88M—$0————
Current assets$165.59M$177.68M$197.48M$60.84M$71.53M$84.55M$98.17M$113.00M
PP&E, net$414,000$435,000$519,000$618,000$720,000$821,000$925,000$1.02M
Total assets$167.08M$179.35M$198.69M$62.12M$72.83M$86.07M$99.88M$114.91M
Current liabilities$8.79M$6.64M$14.33M$5.92M$6.25M$7.60M$8.79M$10.53M
Total liabilities$9.34M$7.25M$14.34M$5.93M$6.41M$7.90M$9.23M$11.08M
Shareholders' equity$157.74M$172.11M$184.35M$56.18M$66.43M$78.17M$90.65M$103.83M
Cash flow statement
Operating cash flow-$13.08M-$10.35M-$12.94M-$11.51M-$13.04M-$13.27M-$14.01M-$21.02M
Capital expenditure$32,000$3,000$5,000$9,000$6,000$13,000$18,000$50,000
Free cash flow-$13.11M-$10.36M-$12.94M-$11.52M-$13.04M-$13.29M-$14.02M-$21.07M
Investing cash flow-$1.97M-$9.87M-$5,000-$9,000-$6,000-$13,000-$18,000-$45.38M
Financing cash flow-$8,000-$5.38M$146.00M$240,000$0$0-$77,000$114.22M
Depreciation & amortization$53,000$87,000$104,000$104,000$108,000$117,000$118,000$419,000
Stock-based compensation$3.49M$3.05M$2.78M$3.02M$2.96M$2.91M$2.75M$1.64M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.